Overview

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Status:
Active, not recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

REMD Biotherapeutics, Inc.

Treatments:

Volagidemab